John Garner

PLGA-NH2 from PolySciTech used in development of lung-targeting polymeric microdiscs to treat pulmonary disease

Blog Post created by John Garner on Jul 9, 2019

Most drugs administered into the blood stream are rapidly cleared by the body and either metabolized into some other form or removed into the urine or excreted by some other manner. This limits the efficacy of these medicinal compounds. Recently, researchers at Yonsei University and Korea Institute of Radiological and Medical Sciences (Korea) used PLGA-NH2 (AI010) from PolySciTech ( to develop microdiscs designed to accumulate to the lungs. This research holds promise to improve therapies against pulmonary diseases. Read more: Park, Jun Young, Sanghyo Park, Tae Sup Lee, Yong Hwa Hwang, Jung Young Kim, Won Jun Kang, and Jaehong Key. "Biodegradable micro-sized discoidal polymeric particles for lung-targeted delivery system." Biomaterials (2019): 119331.


“Abstract: Various types of particle-based drug delivery systems have been explored for the treatment of pulmonary diseases; however, bio-distribution and elimination of the particles should be monitored for better understanding of their therapeutic efficacy and safety. This study aimed to characterize the biological properties of micro-sized discoidal polymeric particles (DPPs) as lung-targeted drug delivery carriers. DPPs were prepared using a top-down fabrication approach and characterized by assessing size and zeta potential. They were labeled with zirconium-89 (89Zr), and bio-distribution studies and PET imaging were performed for 7 days after intravenous administration. Their hydrodynamic size was 2.8 ± 6.1 μm and average zeta potential was −39.9 ± 5.39 mV. At doses of 5, 12.5, and 25 mg/kg, they showed no acute toxicity in nude mice. Desferrioxamine (DFO)-functionalized 89Zr-labeled DPPs gave a decay-corrected radiochemical yield of 82.1 ± 0.2%. Furthermore, 89Zr-DPPs, from chelate-free labeling methods, showed a yield of 48.5 ± 0.9%. Bio-distribution studies and PET imaging showed 89Zr-DFO-DPPs to be mainly accumulated in the lungs and degraded within 3 d of injection. However, 89Zr-DFO-DPPs showed significantly low uptake in the bone. Overall, our results suggested micro-sized DPPs as promising drug delivery carriers for the targeted treatment of various pulmonary diseases. Keywords: Drug delivery system Discoidal polymeric particle Pulmonary disease Zr-89 PET imaging”


Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at